Clinical Trial: Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Peripheral T Cell Lymphoma
Study Type: INTERVENTIONAL
Official Title: Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Brief Summary:
This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety, tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with relapsed/refractory peripheral T/NK cell lymphoma.Around 7-18 patients will be subsequently enrolled into 3 different dose ascending cohorts.Additional 12-18 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.
Read more